⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMTX News
Immatics N.V. Ordinary Shares
Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease
globenewswire.com
IMUX
IMTX
Immatics Announces $150 Million Underwritten Offering
globenewswire.com
IMTX
Immatics Announces Second Quarter 2026 Financial Results and Business Update
globenewswire.com
IMTX
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
globenewswire.com
IMTX
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
prnewswire.com
IMTX
SNY
PFE
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
globenewswire.com
IMTX
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
globenewswire.com
IMTX
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
globenewswire.com
IMTX
Immatics Announces First Quarter 2026 Financial Results and Business Update
globenewswire.com
IMTX
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
globenewswire.com
IMTX